menu search
Trades24h logo
 Register
close Tap here to search
  1. Home

  2. News

  3. Stock Details

Subscribe To  

  Price Alert   Latest News   Economic Calendar News

ARGX / argenx SE (ARGX) Q3 2023 Earnings Call Transcript

argenx SE (ARGX) Q3 2023 Earnings Call Transcript
argenx SE (NASDAQ:ARGX ) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Beth DelGiacco - VP and Global Head, Corporate Communications and IR Tim Van Hauwermeiren - CEO Karl Gubitz - CFO Karen Massey - COO Conference Call Participants Yatin Suneja - Guggenheim Partners Tazeen Ahmad - Bank of America Derek Archila - Wells Fargo Thomas Smith - Leerink Partners James Gordon - JPMorgan Amy Li - Jefferies Danielle Brill - Raymond James Yaron Werber - TD Cowen Myles Minter - William Blair Joel Beatty - Baird Alex Thompson - Stiefel Allison Bratzel - Piper Sandler Vikram Purohit - Morgan Stanley Manos Mastorakis - Deutsche Bank Douglas Tsao - H.C. Wainwright Joon Lee - Truist Securities Suzanne van Voorthuizen - VLK Samantha Semenkow - Citi Rajan Sharma - Goldman Sachs Charles Pitman - Barclays Operator Good morning. Read More
Hmarkets Logo
Demo chevron_right Live Account chevron_right See Partner Details

Content Topics

Argenx

ARGX

2023

Earnings

Call

Transcript

argx

Stock

Posted: Oct 31 2023, 15:32
Author Name: Seeking Alpha
Views: 092084

ARGX News  

argenx to Present at Upcoming Investor Conferences

By GlobeNewsWire
November 1, 2023

argenx to Present at Upcoming Investor Conferences

November 1, 2023 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of peop more_horizontal

argenx SE (ARGX) Q3 2023 Earnings Call Transcript

By Seeking Alpha
October 31, 2023

argenx SE (ARGX) Q3 2023 Earnings Call Transcript

argenx SE (NASDAQ:ARGX ) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Beth DelGiacco - VP and Global Head, Corpor more_horizontal

argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023

By GlobeNewsWire
October 24, 2023

argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023

October 24, 2023 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of peop more_horizontal

argenx: Efgartigimod Is Not Just A Drug, A Cornerstone

By Seeking Alpha
October 17, 2023

argenx: Efgartigimod Is Not Just A Drug, A Cornerstone

argenx exhibits robust financials with a Q2 YoY net sales surge to $269.3M and liquidity of $2.0B but faces increasing operating costs and R&D expendi more_horizontal

Argenx's 28% Surge & Promising Product Propel Investor Confidence

By MarketBeat
September 25, 2023

Argenx's 28% Surge & Promising Product Propel Investor Confidence

The stock gapped up nearly 28% on July 17, after announcing better-than-expected results from a clinical trial of its treatment for patients suffering more_horizontal

argenx to Present at Upcoming Investor Conferences

By GlobeNewsWire
August 30, 2023

argenx to Present at Upcoming Investor Conferences

August 30 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of pe more_horizontal

Why Shares of Argenx Jumped This Week

By The Motley Fool
July 21, 2023

Why Shares of Argenx Jumped This Week

Argenx has only two approved therapies, Vyvgart and Vyvgart Hytrulo. Vyvgart Hytrulo fared well in a trial to treat adults with chronic inflammatory d more_horizontal

argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023

By GlobeNewsWire
July 20, 2023

argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023

July 20 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of peop more_horizontal

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

©2014-2024 All Rights Reserved. I.C

Hand-crafted & made with Love

logo close

Search within

Pages Search Results: